Bleeding diathesis: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(32 intermediate revisions by 3 users not shown)
Line 4: Line 4:
{{CMG}}; {{AE}} {{MJ}}, {{N.F}}, {{S.G.}}
{{CMG}}; {{AE}} {{MJ}}, {{N.F}}, {{S.G.}}


{{SK}}  Hypocoagulopathy; Bleeding disorders.
{{SK}}  Hypocoagulopathy; blood coagulation disorders; hemorrhagic diathesis; hemostasis abnormality; bleeding tendency
 


== Overview ==
== Overview ==
Bleeding diathesis is susceptibility to bleed due to [[Coagulopathy|coagulopathy disorders]] or platelets disorders. These diseases can occur due to a disorder of [[homeostasis]], localized process ([[tissue]] injury), or [[Medication|medications]]. Bleeding diathesis can be resulted from [[vessel wall]] injury, [[platelet]] disorders, and [[coagulation factor]] disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. [[Platelet]] disorders mostly have skin manifestations such as [[Petechia|petechiae]], and  [[ecchymoses]]. In order to find the cause of hypo-[[coagulopathy]]; there are established laboratory tests, such as [[peripheral blood smear]], [[platelet]] count and [[platelet]] function analysis, [[coagulation factor]] deficiencies and inhibitors, [[fibrinolysis]] tests (eg. [[D-dimer]] level), [[bleeding time|bleeding time (BT)]], [[prothrombin time|prothrombin time (PT)]], [[Partial thromboplastin time|activated partial thromboplastin time (aPTT)]], [[thrombin time]] (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are [[Complete blood count|CBC]], [[PT]], [[Partial thromboplastin time|PTT]], [[Bleeding time|BT]], and [[Thrombin time|TT]].<ref name="pmid12958618">{{cite journal |vauthors=Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL |title=Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice |journal=Thromb. Haemost. |volume=90 |issue=3 |pages=483–90 |date=September 2003 |pmid=12958618 |doi=10.1160/TH03-02-0111 |url=}}</ref>
Bleeding diathesis is susceptibility to bleed due to [[Coagulopathy|coagulopathy disorders]] or [[platelets]] disorders. These diseases can occur due to a disorder of [[homeostasis]], localized process ([[tissue]] injury), or [[Medication|medications]]. Bleeding diathesis can be resulted from [[vessel wall]] injury, [[platelet]] disorders, and [[coagulation factor]] disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. [[Platelet]] disorders mostly have skin manifestations such as [[Petechia|petechiae]], and  [[ecchymoses]]. In order to find the cause of hypo-[[coagulopathy]]; there are established laboratory tests, such as [[peripheral blood smear]], [[platelet]] count and [[platelet]] function analysis, [[coagulation factor]] deficiencies and inhibitors, [[fibrinolysis]] tests (eg. [[D-dimer]] level), [[bleeding time|bleeding time (BT)]], [[prothrombin time|prothrombin time (PT)]], [[Partial thromboplastin time|activated partial thromboplastin time (aPTT)]], [[thrombin time]] (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are [[Complete blood count|CBC]], [[PT]], [[Partial thromboplastin time|PTT]], [[Bleeding time|BT]], and [[Thrombin time|TT]].


== Classification ==
== Classification ==
Line 14: Line 15:
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | A01=Abnormal hemostasis }}  
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | A01=Abnormal hemostasis }}  
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | |B01=<br>•Patient history-sign & symptom: Deep soft tissue bleeding Mucocutaneus bleeding <br>•Screen test CBBC-plt-PT&PTT-BT-TT }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | |B01=<br>• Patient history-sign & symptom: deep soft tissue & mucocutaneus bleeding <br>• Screen test CBC-Plt-PT&PTT-BT-TT }}
{{familytree | | | | | | | | | | | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | B02 | | | | | | | | |B01=Hx of deep soft tissue bleeding |B02=Hx of mucocotaneus bleeding | | | }}
{{familytree | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | B02 | | | | | | | | |B01=Hx of deep soft tissue bleeding |B02=Hx of mucocotaneus bleeding | | | }}
{{familytree | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | | | | | C02 | | | | | | | | |C01=Coagulopathy |C02=Plt disorder | | | }}
{{familytree | | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | | | | | C02 | | | | | | | | |C01=Coagulopathy |C02=Plt disorder | | | }}
Line 22: Line 23:
{{familytree | | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | D02 | | | D03 | | | | | | | |D01=Family history |D02=Normal plt count |D03=Low plt count | | | }}
{{familytree | | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | D02 | | | D03 | | | | | | | |D01=Family history |D02=Normal plt count |D03=Low plt count | | | }}
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | E01 | | | | | | | | | | | | | | | | | | | E02 | | | | | | | E03 | | | | | | |E01=(+)<br>•Inherited coagulpathy |E02=(-)<br>•Aquired coagulopathy |E03=Functional Plt disorder | | |}}
{{familytree | | | | | E01 | | | | | | | | | | | | | | | | | | | E02 | | | | | | | E03 | | | | | | |E01=(+)<br>• Inherited coagulpathy |E02=(-)<br>• Acquired coagulopathy |E03=Functional Plt disorder | | |}}
{{familytree | |,|-|-|-|+|-|-|-|.| | | | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|-|-|-|.| |!| | | }}
{{familytree | |,|-|-|-|+|-|-|-|.| | | | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|-|-|-|.| |!| | | }}
{{familytree | F01 | | F02 | | F03 | | | F04 | | F05 | | F06 | | F07 | | | | | F08 |!| | | |F01=↑Plt <br>•Hemophillia <br>•VWD <br>•FactorVIII or IX deficiency |F02=↑PT <br>• Factor VII deficiensy |F03=↑PT&↑PTT <br>•Fibrinogen deficiency <br>•FactorII deficiency <br>•FactorV deficiency <br>•FactorX deficiency |F04=↑PTT <br>•Factor inhibitor <br>•Anti phospholipid A6syndrome |F05=↑PT <br>•Factor inhibitor <br>•VitK deficiency <br>•Liver disease |F06=↑PT&↑PTT <br>•Factor inhibit <br>•DIC <br>•Liver failure <br>•late stage of VitK deficincy |F07=↑Afibrinogenia <br>•Heparin inhibitor <br>•Direct thrombin inhibitor |F08=Abnormal solobity <br>•FactorXIII deficincy <br>•Cross-linkin inhibitor | | |}}
{{familytree | F01 | | F02 | | F03 | | | F04 | | F05 | | F06 | | F07 | | | | | F08 |!| | | |F01=↑Plt <br>• Hemophillia <br>• VWD <br>• Factor VIII or IX deficiency |F02=↑PT <br>• Factor VII deficiency |F03=↑PT&↑PTT <br>• Fibrinogen deficiency <br>• Factor II deficiency <br>• Factor V deficiency <br>• Factor X deficiency |F04=↑PTT <br>• Factor inhibitor <br>• Anti phospholipid Ab syndrome |F05=↑PT <br>• Factor inhibitor <br>• Vit K deficiency <br>• Liver disease |F06=↑PT&↑PTT <br>• Factor inhibit <br>• DIC <br>• Liver failure <br>• Late stage of Vit K deficiency |F07=↑ Afibrinogenemia <br>• Heparin inhibitor <br>• Direct thrombin inhibitor |F08=Abnormal solobity <br>• Factor XIII deficiency <br>• Cross-linkin inhibitor | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |,|-|^|-|.| | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |,|-|^|-|.| | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | G01 | | | | | | | | | G02 | | G03 |G01=Not corrected with mixing with NL plasma |G02=HX(+) |G03=HX(-) | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | G01 | | | | | | | | | G02 | | G03 |G01=Not corrected with mixing with NL plasma |G02=HX(+) |G03=HX(-) | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |!| | | |!| | | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |!| | | |!| | | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | H01 | | | | | | | | | H02 | | H03 | | |H01=<br>•Factor inhibitors <br>•Lupus anti coagulant <br>•DIC <br>•Heparin or direct thrombin inhibitors |H02=Congenital |H03=Acquired | | | }}   
{{familytree | | | | | | | | | | | | | | | | | | | | | | H01 | | | | | | | | | H02 | | H03 | | |H01=<br>• Factor inhibitors <br>• Lupus anti coagulant <br>• DIC <br>• Heparin or direct thrombin inhibitors |H02=Congenital |H03=Acquired | | | }}   
{{Family tree/end}}
{{Family tree/end}}


=== [[Platelet]] disorders: ===
== Differentiating Bleeding Disorders from Other Diseases ==
# [[Thrombocytopenia]]: [[platelet]] count less than 150,000 per mm<sup>3</sup>
Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.  
# Thromobcytosis: [[platelet]] count more than 450,000 per mm<sup>3</sup>
# Qualitative Disorders of [[Platelet]] function such as [[Von Willebrand disease|Von Willebrand Disease]], inherited or acquired functional disorders.
 
=== Coagulation disorders ===
# Vessel wall disorders: [[Endothelial cells]] are lining entire vessel walls all over the body. [[Endothelium]] is an active layer responsible for [[Inflammation|inflammatory responses]], [[angiogenesis]] and [[blood cell]] interactions. [[Endothelial cells]] have a very important role in [[hemostasis]] and they are regulating blood fluidity by the balance of [[antithrombotic]]/prothrombotic and [[vasodilatory]]/[[vasoconstrictor]] effects.
#* [[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
#* Inherited Disorders of the [[Vessel wall|Vessel Wall]]
# Coagulation factor disorders:
#* [[Fibrinogen]] deficiency
#* [[Prothrombin deficiency]]
#* [[Factor V deficiency]]
#* [[Factor VII deficiency]]
#* [[Factor X deficiency]]
#* [[Factor XII|Factor XII deficiency]]
#* HK deficiency
#* [[Prekallikrein]] deficiency
#* [[Factor XIII deficiency]]
#* [[Hemophilia]]
# [[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
# [[Vitamin K Deficiency]]
# Coagulation Disorders Associated with [[Hepatic failure|Liver Failure]]
# Acquired Inhibitors of Coagulation Factors
 
== Differential Diagnosis ==
Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.  


These features have discussed in the below table:
These features have discussed in the below table:
{| class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;"
{|  
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-category
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Diseases
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
Line 71: Line 47:
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |<nowiki>Petechia|Petechiae</nowiki>
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Platelet count
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding time (BT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Prothrombin time (PT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Activated partial thromboplastin time (aPTT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Thrombin time (TT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
|-
|-
! rowspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |[[Platelet]] disorders
! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span><ref name="pmid21325604">{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |date=April 2011 |pmid=21325604 |doi=10.1182/blood-2010-08-302984 |url=}}</ref><ref name="pmid26906627">{{cite journal |vauthors=Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP |title=Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection |journal=Lancet |volume=387 |issue=10022 |pages=939–940 |date=March 2016 |pmid=26906627 |doi=10.1016/S0140-6736(16)00502-X |url=}}</ref><ref name="pmid25600600">{{cite journal |vauthors=Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J |title=Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications |journal=J. Clin. Virol. |volume=63 |issue= |pages=32–5 |date=February 2015 |pmid=25600600 |doi=10.1016/j.jcv.2014.12.005 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<ref name="HerbingerSchunk2012">{{cite journal|last1=Herbinger|first1=K.-H.|last2=Schunk|first2=M.|last3=Nothdurft|first3=H. D.|last4=von Sonnenburg|first4=F.|last5=Löscher|first5=T.|last6=Bretzel|first6=G.|title=Comparative study on infection-induced thrombocytopenia among returned travellers|journal=Infection|volume=40|issue=4|year=2012|pages=373–379|issn=0300-8126|doi=10.1007/s15010-012-0242-9}}</ref>
|
 
| align="left" style="background:#F5F5F5;" |  
* History of prior infection
* History of prior infection
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]] <ref name="pmid25134884">{{cite journal |vauthors=Kam T, Alexander M |title=Drug-induced immune thrombocytopenia |journal=J Pharm Pract |volume=27 |issue=5 |pages=430–9 |date=October 2014 |pmid=25134884 |doi=10.1177/0897190014546099 |url=}}</ref><ref name="pmid23461497">{{cite journal |vauthors=Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L |title=[Incidence of drug-induced thrombocytopenia in hospitalized patients] |language=Spanish; Castilian |journal=Farm Hosp |volume=37 |issue=1 |pages=27–34 |date=2013 |pmid=23461497 |doi=10.7399/FH.2013.37.1.42 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication]]-Induced [[Thrombocytopenia|Thrombocytopenia]]<ref name="EltingCantor2003">{{cite journal|last1=Elting|first1=Linda S.|last2=Cantor|first2=Scott B.|last3=Martin|first3=Charles G.|last4=Hamblin|first4=Lois|last5=Kurtin|first5=Danna|last6=Rivera|first6=Edgardo|last7=Vadhan-Raj|first7=Saroj|last8=Benjamin|first8=Robert S.|title=Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors|journal=Cancer|volume=97|issue=6|year=2003|pages=1541–1550|issn=0008-543X|doi=10.1002/cncr.11195}}</ref>
|
| align="left" style="background:#F5F5F5;" |  
*History of [[Medication|medications]] such as:
*History of [[Medication|medications]] such as:
** [[Furosemide]]
** [[Furosemide]]
Line 111: Line 88:
** [[Sulfonamide (medicine)|Sulfonamides]]
** [[Sulfonamide (medicine)|Sulfonamides]]
** [[Linezolid]]  
** [[Linezolid]]  
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Most important par of treatment is discontinuing of the medication.
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span><ref name="pmid25629757">{{cite journal |vauthors=Warkentin TE, Safyan EL, Linkins LA |title=Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages |journal=N. Engl. J. Med. |volume=372 |issue=5 |pages=492–4 |date=January 2015 |pmid=25629757 |doi=10.1056/NEJMc1414161 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<ref name="Miller2003">{{cite journal|last1=Miller|first1=Penny L.|title=Heparin-induced Thrombocytopenia Recognition and Treatment|journal=AORN Journal|volume=78|issue=1|year=2003|pages=79–89|issn=00012092|doi=10.1016/S0001-2092(06)61348-3}}</ref>
|
| align="left" style="background:#F5F5F5;" |  
* [[Thrombosis]]
* [[Thrombosis]]
* Unexplained [[thrombocytopenia]] up to 3 weeks after the end of [[heparin]] therapy
* Unexplained [[thrombocytopenia]] up to 3 weeks after the end of [[heparin]] therapy
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|↑
| align="center" style="background:#F5F5F5;" | ↑
|For more information click here: [[Heparin-induced thrombocytopenia]].  
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span><ref name="pmid8857953">{{cite journal |vauthors=Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J |title=Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP) |journal=Br. J. Haematol. |volume=95 |issue=1 |pages=145–52 |date=October 1996 |pmid=8857953 |doi= |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]]<ref name="CurtisKaliszewski2006">{{cite journal|last1=Curtis|first1=Brian R.|last2=Kaliszewski|first2=James|last3=Marques|first3=Marisa B.|last4=Saif|first4=M. Wasif|last5=Nabelle|first5=Lisle|last6=Blank|first6=Jules|last7=McFarland|first7=Janice G.|last8=Aster|first8=Richard H.|title=Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin|journal=American Journal of Hematology|volume=81|issue=3|year=2006|pages=199–201|issn=0361-8609|doi=10.1002/ajh.20516}}</ref>
|
| align="left" style="background:#F5F5F5;" |  
* History of prior [[infection]] or no history
* History of prior [[infection]] or no history
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
| -
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span><ref name="pmid27025194">{{cite journal |vauthors=Johnson B, Fletcher SJ, Morgan NV |title=Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan |journal=Platelets |volume=27 |issue=6 |pages=519–25 |date=September 2016 |pmid=27025194 |pmc=5000870 |doi=10.3109/09537104.2016.1148806 |url=}}</ref><ref name="pmid30103613">{{cite journal |vauthors=Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M |title=Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia |journal=Clin. Appl. Thromb. Hemost. |volume= |issue= |pages=1076029618790696 |date=August 2018 |pmid=30103613 |doi=10.1177/1076029618790696 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<ref name="Drachman2004">{{cite journal|last1=Drachman|first1=J. G.|title=Inherited thrombocytopenia: when a low platelet count does not mean ITP|journal=Blood|volume=103|issue=2|year=2004|pages=390–398|issn=0006-4971|doi=10.1182/blood-2003-05-1742}}</ref>
|
| align="left" style="background:#F5F5F5;" |  
* Family history
* Positive family history
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
| -
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span><ref name="pmid30220931">{{cite journal |vauthors=Knöbl P |title=Thrombotic thrombocytopenic purpura |journal=Memo |volume=11 |issue=3 |pages=220–226 |date=2018 |pmid=30220931 |doi=10.1007/s12254-018-0429-6 |url=}}</ref><ref name="pmid26386489">{{cite journal |vauthors=Mannucci PM, Cugno M |title=The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring |journal=Thromb. Res. |volume=136 |issue=5 |pages=851–4 |date=November 2015 |pmid=26386489 |doi=10.1016/j.thromres.2015.09.007 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]]<ref name="George2006">{{cite journal|last1=George|first1=James N.|title=Thrombotic Thrombocytopenic Purpura|journal=New England Journal of Medicine|volume=354|issue=18|year=2006|pages=1927–1935|issn=0028-4793|doi=10.1056/NEJMcp053024}}</ref>
|History of:
| align="left" style="background:#F5F5F5;" | History of:
*[[Cancer]]
*[[Cancer]]
*[[Bone marrow transplantation]]
*[[Bone marrow transplantation]]
Line 182: Line 159:
**Immunosuppressants ([[cyclosporine]], [[mitomycin]], [[tacrolimus]]/FK506, [[interferon|interferon-α]])
**Immunosuppressants ([[cyclosporine]], [[mitomycin]], [[tacrolimus]]/FK506, [[interferon|interferon-α]])
*[[HIV-1]] infection
*[[HIV-1]] infection
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
| -
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span><ref name="pmid24365375">{{cite journal |vauthors=Webster K, Schnitzler E |title=Hemolytic uremic syndrome |journal=Handb Clin Neurol |volume=120 |issue= |pages=1113–23 |date=2014 |pmid=24365375 |doi=10.1016/B978-0-7020-4087-0.00075-9 |url=}}</ref><ref name="pmid25845294">{{cite journal |vauthors=Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P |title=Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome |journal=Pathol. Biol. |volume=63 |issue=3 |pages=136–43 |date=June 2015 |pmid=25845294 |doi=10.1016/j.patbio.2015.03.001 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<ref name="Noris2005">{{cite journal|last1=Noris|first1=M.|title=Hemolytic Uremic Syndrome|journal=Journal of the American Society of Nephrology|volume=16|issue=4|year=2005|pages=1035–1050|issn=1046-6673|doi=10.1681/ASN.2004100861}}</ref>
|History of:
| align="left" style="background:#F5F5F5;" |History of:
* Infections
* [[Infections]]
 
* [[Malignancy]], [[chemotherapy]], and [[ionizing radiation]]
* [[Malignancy]], [[Cancer (disease)|cancer]] [[chemotherapy]] and [[ionizing radiation]]
* [[Calcineurin inhibitor]]s and [[transplantation]]
* [[Calcineurin inhibitor]]<nowiki/>s and [[transplantation]]
* [[Pregnancy]], [[HELLP syndrome]], and [[oral contraceptive pill]]
* [[Pregnancy]], [[HELLP syndrome]] and [[oral contraceptive pill]]
* [[Systemic lupus erythematosis]]   
* [[Systemic lupus erythematosis]]   
* [[Antiphospholipid syndrome|Antiphospholipid antibody syndrome]]
* [[Antiphospholipid syndrome|Antiphospholipid antibody syndrome]]
* [[Glomerulopathy]]
* [[Glomerulopathy]]
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
| -
| align="center" style="background:#F5F5F5;" | −
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
Line 225: Line 217:


[[Essential thrombocytosis|Essential thrombocytosis]]
[[Essential thrombocytosis|Essential thrombocytosis]]
|
| align="left" style="background:#F5F5F5;" |  
* Digital pain
* Digital [[pain]]
* [[Gangrene]]  
* [[Gangrene]]  
* [[Erythromelalgia]]
* [[Erythromelalgia]]
* Headache
* H[[eadache]]
* [[Paresthesia|Paresthesias]]   
* [[Paresthesia|Paresthesias]]   
* [[Transient ischemic attack|Transient ischemic attacks]]
* [[Transient ischemic attack|Transient ischemic attacks]]
| -
| align="center" style="background:#F5F5F5;" | −
|−
| align="center" style="background:#F5F5F5;" | −
|−
| align="center" style="background:#F5F5F5;" | −
|−
| align="center" style="background:#F5F5F5;" | −
| +/-
| align="center" style="background:#F5F5F5;" |±
| +/-
| align="center" style="background:#F5F5F5;" |±
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal/
| align="center" style="background:#F5F5F5;" | Nl or
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
| -
| align="center" style="background:#F5F5F5;" | −
|-
|-
! rowspan="5" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Qualitative Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span>
! rowspan="6" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Qualitative Disorders of [[Platelet]] Function
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span>
! rowspan="4" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of [[Platelet]] Function
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Glanzmann's thrombasthenia|Glanzmann’s thrombasthenia]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Glanzmann's thrombasthenia|Glanzmann’s thrombasthenia]]
|
| align="left" style="background:#F5F5F5;" |  
* Family history
* Positive family history
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| -
| align="center" style="background:#F5F5F5;" | −
|Rare
| align="center" style="background:#F5F5F5;" | Rare
|Normal/
| align="center" style="background:#F5F5F5;" | Nl or
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|
| align="left" style="background:#F5F5F5;" |  
* AR inheritance
* AR inheritance
* Absence of the platelet Gp IIb/IIIa receptor/
* Absence of the platelet Gp IIb/IIIa receptor
* Diminished for GP 2B-3A on [[Flow cytometry|f<abbr>low cytometry</abbr>]]  
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]<ref name="pmid30077511">{{cite journal |vauthors=Dupuis A, Gachet C |title=Inherited platelet disorders : Management of the bleeding risk |journal=Transfus Clin Biol |volume=25 |issue=3 |pages=228–235 |date=September 2018 |pmid=30077511 |doi=10.1016/j.tracli.2018.07.003 |url=}}</ref><ref name="pmid29227167">{{cite journal |vauthors=Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H |title=Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach |journal=Platelets |volume=29 |issue=4 |pages=347–356 |date=June 2018 |pmid=29227167 |doi=10.1080/09537104.2017.1386297 |url=}}</ref>
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]
|
| align="left" style="background:#F5F5F5;" |  
* Family history
* Positive family history
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| -
| align="center" style="background:#F5F5F5;" |
| -
| align="center" style="background:#F5F5F5;" |
|Normal/↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
|
| align="center" style="background:#F5F5F5;" |
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|
| align="left" style="background:#F5F5F5;" |  
* AR inheritance
* AR inheritance
* Absence of the platelet Gp Ib-IX-V receptor
* Absence of the platelet Gp Ib-IX-V receptor
Line 286: Line 278:
* Ristocetin - no aggregation
* Ristocetin - no aggregation
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" |[[Platelet storage pool deficiency|Platelet storage pool disorder (SPD)]]:  
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]
| align="left" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
* In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
|-
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |Platelet storage pool disorder:  
*[[Hermansky-Pudlak syndrome]]
*[[Hermansky-Pudlak syndrome]]
*[[Chediak-Higashi syndrome]]
*[[Chediak-Higashi syndrome]]
*[[Gray platelet syndrome]]
*[[Gray platelet syndrome]]
|
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
*Hairy-cell leukemia
* [[Hairy cell leukemia]]
* Cardiovascular bypass
* [[Cardiovascular bypass]]
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| -
| align="center" style="background:#F5F5F5;" | −
| -
| align="center" style="background:#F5F5F5;" | −
|Normal/
| align="center" style="background:#F5F5F5;" | Nl or
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|
| align="left" style="background:#F5F5F5;" |  
* AD inheritance
* AD inheritance
* Abnormalities of platelet granule formation
* Abnormlities of platelet granule formation
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function
! style="padding: 5px 5px; background: #DCDCDC;" |
| align="left" style="background:#F5F5F5 " |
* [[Chronic renal failure pathophysiology|Uremia]]
* [[Chronic renal failure pathophysiology|Uremia]]
* Cardiopulmonary bypass
* [[Cardiopulmonary bypass]]
* Hematologic disorders such as: [[Myeloproliferative disease|myeloproliferative]] and [[Myelodysplastic syndrome|myelodysplastic syndromes]]
* Hematologic disorders such as: [[Myeloproliferative disease|myeloproliferative]] and [[Myelodysplastic syndrome|myelodysplastic syndromes]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| +/-
| align="center" style="background:#F5F5F5;" |±
| +/-
| align="center" style="background:#F5F5F5;" |±
|Normal/
| align="center" style="background:#F5F5F5;" | Nl or
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid16985174">{{cite journal |vauthors=Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I |title=Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) |journal=Blood |volume=109 |issue=1 |pages=112–21 |date=January 2007 |pmid=16985174 |doi=10.1182/blood-2006-05-020784 |url=}}</ref><ref name="pmid9579642">{{cite journal |vauthors=Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ |title=PFA-100 system: a new method for assessment of platelet dysfunction |journal=Semin. Thromb. Hemost. |volume=24 |issue=2 |pages=195–202 |date=1998 |pmid=9579642 |doi=10.1055/s-2007-995840 |url=}}</ref><ref name="pmid258585642">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]  
 
| align="left" style="background:#F5F5F5;" |  
|
* Easy bruising
* Easy bruising
* [[Epistaxis]]
* [[Epistaxis]]
Line 336: Line 345:
* [[Menorrhagia]]
* [[Menorrhagia]]
* [[Postpartum hemorrhage]]
* [[Postpartum hemorrhage]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| +/-
| align="center" style="background:#F5F5F5;" |±
| +/-
| align="center" style="background:#F5F5F5;" |±
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|↑
| align="center" style="background:#F5F5F5;" | ↑
|↑
| align="center" style="background:#F5F5F5;" | ↑
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|See the table below for the details about types.
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! rowspan="2" align="center" style="padding: 5px 5px; background: #4479BA;" |Vessel wall disorders
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
* Acute febrile illnesses
* Acute febrile illnesses
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
* [[Monoclonal gammopathy|Monoclonal gammopathies]]
* [[Monoclonal gammopathy|Monoclonal gammopathies]]
* Certain pathogens, such as the rickettsiae causing [[Rocky Mountain spotted fever]]
* [[Rocky Mountain spotted fever]]
* [[Vitamin C]] deficiency
* [[Vitamin C deficiency]]
* [[Cushing's syndrome|Cushing’s syndrome]]  
* [[Cushing's syndrome|Cushing’s syndrome]]  
* Chronic [[glucocorticoid]] therapy  
* Chronic [[glucocorticoid]] therapy  
* [[Ageing|Aging]] 
* [[Vasculitis]] such as Henoch-Schönlein Purpura
* [[Vasculitis]] such as Henoch-Schönlein,
| align="left" style="background:#F5F5F5;" |
|
* History of the underlying disease
* History of the underlying disease.
| align="center" style="background:#F5F5F5;" |−
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>+/-</nowiki>
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl or
|↑/Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |−
|<nowiki>-</nowiki>
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" align="left" style="background:#DCDCDC;" |
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Ehlers-Danlos syndrome]]
* [[Ehlers-Danlos syndrome]]
* [[Pseudoxanthoma elasticum]]
* [[Pseudoxanthoma elasticum]]
* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
|
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+/-</nowiki>
| align="center" style="background:#F5F5F5;" |±
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑/Normal
| align="center" style="background:#F5F5F5;" |Nl or
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! rowspan="12" align="center" style="padding: 5px 5px; background: #4479BA;" |Coagulation factor disorders<ref name="pmid29027765">{{cite journal |vauthors=Karimi M, Peyvandi F, Naderi M, Shapiro A |title=Factor XIII deficiency diagnosis: Challenges and tools |journal=Int J Lab Hematol |volume=40 |issue=1 |pages=3–11 |date=February 2018 |pmid=29027765 |doi=10.1111/ijlh.12756 |url=}}</ref><ref name="pmid27590165">{{cite journal |vauthors=Peyvandi F, Garagiola I, Biguzzi E |title=Advances in the treatment of bleeding disorders |journal=J. Thromb. Haemost. |volume=14 |issue=11 |pages=2095–2106 |date=November 2016 |pmid=27590165 |doi=10.1111/jth.13491 |url=}}</ref><ref name="pmid28966616">{{cite journal |vauthors=Bender L, Weidmann H, Rose-John S, Renné T, Long AT |title=Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis |journal=Front Immunol |volume=8 |issue= |pages=1115 |date=2017 |pmid=28966616 |pmc=5605561 |doi=10.3389/fimmu.2017.01115 |url=}}</ref><ref name="pmid28966616" /><ref name="pmid27380557">{{cite journal |vauthors=Schmaier AH |title=Antithrombotic potential of the contact activation pathway |journal=Curr. Opin. Hematol. |volume=23 |issue=5 |pages=445–52 |date=September 2016 |pmid=27380557 |pmc=5148823 |doi=10.1097/MOH.0000000000000271 |url=}}</ref><ref name="pmid26565070">{{cite journal |vauthors=Schmaier AH |title=The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities |journal=J. Thromb. Haemost. |volume=14 |issue=1 |pages=28–39 |date=January 2016 |pmid=26565070 |doi=10.1111/jth.13194 |url=}}</ref><ref name="pmid20580091">{{cite journal |vauthors=Kaplan AP, Ghebrehiwet B |title=The plasma bradykinin-forming pathways and its interrelationships with complement |journal=Mol. Immunol. |volume=47 |issue=13 |pages=2161–9 |date=August 2010 |pmid=20580091 |doi=10.1016/j.molimm.2010.05.010 |url=}}</ref><ref name="pmid22185738">{{cite journal |vauthors=Zuraw BL, Christiansen SC |title=Pathophysiology of hereditary angioedema |journal=Am J Rhinol Allergy |volume=25 |issue=6 |pages=373–8 |date=2011 |pmid=22185738 |doi=10.2500/ajra.2011.25.3661 |url=}}</ref><ref name="pmid23629422">{{cite journal |vauthors=Quail MT |title=Prekallikrein deficiency |journal=J Pediatr Oncol Nurs |volume=30 |issue=4 |pages=198–204 |date=2013 |pmid=23629422 |doi=10.1177/1043454213487436 |url=}}</ref><ref name="pmid27894217">{{cite journal |vauthors=Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, Asadi M, Jalalvand M, Shamsizadeh M |title=Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran |journal=Hematology |volume=22 |issue=4 |pages=224–230 |date=May 2017 |pmid=27894217 |doi=10.1080/10245332.2016.1263007 |url=}}</ref><ref name="pmid29483100">{{cite journal |vauthors=Maas C, Renné T |title=Coagulation factor XII in thrombosis and inflammation |journal=Blood |volume=131 |issue=17 |pages=1903–1909 |date=April 2018 |pmid=29483100 |doi=10.1182/blood-2017-04-569111 |url=}}</ref>
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency<ref name="pmid29844251">{{cite journal |vauthors=Tiscia GL, Margaglione M |title=Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders |journal=Int J Mol Sci |volume=19 |issue=6 |pages= |date=May 2018 |pmid=29844251 |pmc=6032319 |doi=10.3390/ijms19061597 |url=}}</ref>
<ref name="pmid28966616" />
! style="padding: 5px 5px; background: #DCDCDC;" |Different types of the [[fibrinogen]] disorders:
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency
! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
Different types of the [[fibrinogen]] disorders:
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
Line 406: Line 432:
* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
* [[Fibrinogen#Congenital hypodysfibrinogenemia|Congenital hypodysfibrinogenemia]][[Fibrinogen#Cryofibrinogenemia|Cryofibrinogenemia]]
| align="left" style="background:#F5F5F5;" |
* [[Fibrinogen#Acquired hypofibrinogenemia|Acquired hypofibrinogenemia]]
|
* [[Epistaxis]]
* [[Epistaxis]]
* Easy [[Bruise|bruising]]
* Easy [[Bruise|bruising]]
Line 416: Line 440:
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* Bleeding after [[dental surgery]] or tooth extraction
* Bleeding after [[dental surgery]] or tooth extraction
* Abnormal bleeding during or after injury, surgery, or childbirth
* AbNl bleeding during or after injury, surgery, or childbirth
 
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
* [[Cerebral hemorrhage]]
* [[Cerebral hemorrhage]]
* [[Thrombosis]]
* [[Thrombosis]]
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +/-
| align="center" style="background:#F5F5F5;" |±
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|
| align="left" style="background:#F5F5F5;" |
* Impaired fibrin cross linking or clot dissolution.
* Impaired fibrin cross-linking or clot dissolution
 
* Mild or severe bleeding depend on levels of functional fibrinogen
* The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen.  The age of onset is also variable, with earlier onset in those with more severe deficiency.
* Variable age of onset
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Easy [[bruising]]
* [[Epistaxis]]
* [[Epistaxis]]
* Soft-tissue hemorrhage
* Soft-tissue hemorrhage
Line 447: Line 485:
* [[Hemarthrosis]]
* [[Hemarthrosis]]
* [[Intracranial hemorrhage|Intracranial]] bleeding
* [[Intracranial hemorrhage|Intracranial]] bleeding
|
| align="center" style="background:#F5F5F5;" | −
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|↑
| align="center" style="background:#F5F5F5;" | ↑
|↑
| align="center" style="background:#F5F5F5;" | ↑
|↑
| align="center" style="background:#F5F5F5;" | ↑
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
|
| align="left" style="background:#F5F5F5;" |  
* Excessive bruising with minor injuries
* Excessive bruising with minor injuries
* [[Epistaxis]]
* [[Epistaxis]]
Line 468: Line 506:
* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
* [[Pulmonary hemorrhage]]  
* [[Pulmonary hemorrhage]]  
|
| align="center" style="background:#F5F5F5;" | −
|_
| align="center" style="background:#F5F5F5;" | −
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
| align="center" style="background:#F5F5F5;" |
* The severity of bleeding related to the degree of factor V deficiency
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Easy [[Bruise|bruising]]
* Easy [[Bruise|bruising]]
* Mucosal bleeding
* Mucosal bleeding
Line 489: Line 528:
* Soft tissue hematomas
* Soft tissue hematomas
* [[Thrombosis]]  
* [[Thrombosis]]  
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy  
| align="left" style="background:#F5F5F5;" |
* Thrombosis in inherited factor VII deficiency
* Treatment with the administration of factor VII replacement therapy  
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Prolonged bleeding following circumcision
* Prolonged bleeding following circumcision
* Easy [[Bruise|bruising]]
* Easy [[Bruise|bruising]]
* [[Hematuria]]
* [[Hematuria]]
Line 515: Line 555:
* Intracranial bleeding
* Intracranial bleeding
* Hemarthroses
* Hemarthroses
|
| align="center" style="background:#F5F5F5;" |
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Majority,asymptomatic
* Asymptomatic
* Recurrent miscarriages
* Recurrent miscarriages
* Painful leg ulcers
* Painful leg ulcers
|
| align="center" style="background:#F5F5F5;" |
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
|
| align="left" style="background:#F5F5F5;" |
* Possibility of positive family history of bleeding
* Positive family history of bleeding
|
| align="center" style="background:#F5F5F5;" |
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
|
| align="left" style="background:#F5F5F5;" |
* Possibility of positive family history of bleeding
* Positive family history of bleeding
|
| align="center" style="background:#F5F5F5;" |
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|-
|-
! colspan="2" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]<ref>{{cite journal | vauthors =  Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S |display-authors=etal | title = Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis;  |  volume = 41  | issue =  3 (41) | pages = 323–329 | date=2015}}</ref>
! style="padding: 5px 5px; background: #DCDCDC;" |Types:
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |
* Sub unit A mutation disease (more common)
* Sub unit A mutation disease (more common)
* Sub unit B mutation disease
* Sub unit B mutation disease
|
| align="left" style="background:#F5F5F5;" |
* Possibility of positive family history of bleeding
* Positive family history of bleeding
| -/+
| align="center" style="background:#F5F5F5;" |±
| -/+
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal/
| align="center" style="background:#F5F5F5;" |Nl or
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="left" style="background:#F5F5F5;" |
* Impaired fibrin cross linking or clot dissolution
* Impaired fibrin cross-linking or clot dissolution
* The severity of factor XIII deficiency bleeds can be different in different patients  
* The severity of factor XIII deficiency bleeds can be different in different patients  
|-
|-
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid94489952">{{cite journal |vauthors=Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C |title=Rheumatic manifestations of hematologic disorders |journal=Curr Opin Rheumatol |volume=10 |issue=1 |pages=86–90 |date=January 1998 |pmid=9448995 |doi= |url=}}</ref><ref name="pmid16551972">{{cite journal |vauthors=Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR |title=Bleeding in carriers of hemophilia |journal=Blood |volume=108 |issue=1 |pages=52–6 |date=July 2006 |pmid=16551972 |doi=10.1182/blood-2005-09-3879 |url=}}</ref><ref name="pmid25059285">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref><ref name="pmid11307831">{{cite journal |vauthors=White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J |title=Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis |journal=Thromb. Haemost. |volume=85 |issue=3 |pages=560 |date=March 2001 |pmid=11307831 |doi= |url=}}</ref><ref name="pmid24026910">{{cite journal |vauthors=Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G |title=Problems and solutions in laboratory testing for hemophilia |journal=Semin. Thromb. Hemost. |volume=39 |issue=7 |pages=816–33 |date=October 2013 |pmid=24026910 |doi=10.1055/s-0033-1356573 |url=}}</ref><ref name="pmid250592852">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref>
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid26897598">{{cite journal |vauthors=Peyvandi F, Garagiola I, Young G |title=The past and future of haemophilia: diagnosis, treatments, and its complications |journal=Lancet |volume=388 |issue=10040 |pages=187–97 |date=July 2016 |pmid=26897598 |doi=10.1016/S0140-6736(15)01123-X |url=}}</ref>
 
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
|
| align="left" style="background:#F5F5F5;" |
* Eeasy [[Bruise|bruising]]
* Eeasy [[Bruise|bruising]]
* Inadequate clotting in [[trauma]] or mild injury
* Inadequate clotting in [[trauma]] or mild injury
Line 609: Line 664:
* [[Epistaxis]]
* [[Epistaxis]]
* [[Gingival bleeding]]
* [[Gingival bleeding]]
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
|
| align="left" style="background:#F5F5F5;" |
* Neonatal bleeding
* Neonatal bleeding
* Trauma-related soft-tissue hemorrhage
* Trauma-related soft tissue hemorrhage
* [[Hemarthrosis]]   
* [[Hemarthrosis]]   
* [[Hematoma|Hematomas]]  
* [[Hematoma|Hematomas]]  
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
|
| align="left" style="background:#F5F5F5;" |
* Family history  
* Positive family history  
* Bleeding after surgery or injury
* Bleeding after surgery or injury
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|Rare
| align="center" style="background:#F5F5F5;" |Rare
|Rare
| align="center" style="background:#F5F5F5;" |Rare
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
| -
| align="center" style="background:#F5F5F5;" |−
|-
|-
! rowspan="2" align="center" style="padding: 5px 5px; background: #4479BA;" |Rare diseases
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid30008620">{{cite journal |vauthors=Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M |title=Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy |journal=Thromb J |volume=16 |issue= |pages=14 |date=2018 |pmid=30008620 |pmc=6040080 |doi=10.1186/s12959-018-0168-2 |url=}}</ref>
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! style="padding: 5px 5px; background: #DCDCDC;" |
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid580488">{{cite journal |vauthors=Siegal T, Seligsohn U, Aghai E, Modan M |title=Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases |journal=Thromb. Haemost. |volume=39 |issue=1 |pages=122–34 |date=February 1978 |pmid=580488 |doi= |url=}}</ref><ref name="pmid19222477">{{cite journal |vauthors=Levi M, Toh CH, Thachil J, Watson HG |title=Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology |journal=Br. J. Haematol. |volume=145 |issue=1 |pages=24–33 |date=April 2009 |pmid=19222477 |doi=10.1111/j.1365-2141.2009.07600.x |url=}}</ref><ref name="pmid18066597">{{cite journal |vauthors=Ghosh K, Shetty S |title=Blood coagulation in falciparum malaria--a review |journal=Parasitol. Res. |volume=102 |issue=4 |pages=571–6 |date=March 2008 |pmid=18066597 |doi=10.1007/s00436-007-0832-0 |url=}}</ref><ref name="pmid5804882">{{cite journal |vauthors=Siegal T, Seligsohn U, Aghai E, Modan M |title=Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases |journal=Thromb. Haemost. |volume=39 |issue=1 |pages=122–34 |date=February 1978 |pmid=580488 |doi= |url=}}</ref><ref name="pmid1531791">{{cite journal |vauthors=Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P |title=Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies |journal=Chest |volume=101 |issue=3 |pages=816–23 |date=March 1992 |pmid=1531791 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* [[Trauma]]
* [[Trauma]]
* Burn  
* [[Burn]]
* [[Crush injury]]
* [[Crush injury]]
* [[Sepsis]]
* [[Sepsis]]
Line 668: Line 739:
* Obstetric complication: abruption, amniotic fluid embolism
* Obstetric complication: abruption, amniotic fluid embolism
* [[Hemolytic anemia]]
* [[Hemolytic anemia]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|↓
| align="center" style="background:#F5F5F5;" |↓
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
| -
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid26314836">{{cite journal |vauthors=Shiraishi E, Iijima H, Shinzaki S, Nakajima S, Inoue T, Hiyama S, Kawai S, Araki M, Yamaguchi T, Hayashi Y, Fujii H, Nishida T, Tsujii M, Takehara T |title=Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis |journal=J. Gastroenterol. |volume=51 |issue=4 |pages=346–56 |date=April 2016 |pmid=26314836 |doi=10.1007/s00535-015-1112-x |url=}}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid165052572">{{cite journal| author=Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG| title=Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. | journal=Arch Intern Med | year= 2006 | volume= 166 | issue= 4 | pages= 391-7 | pmid=16505257 | doi=10.1001/.391 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16505257  }}</ref>
! style="padding: 5px 5px; background: #DCDCDC;" |
| align="left" style="background:#F5F5F5;" |
* Bleeding after trauma
* Bleeding after trauma
* [[Epistaxis]]
* [[Epistaxis]]
Line 692: Line 763:
* Oozing from venipuncture sites  
* Oozing from venipuncture sites  
* Easy [[Bruise|bruisability]]
* Easy [[Bruise|bruisability]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| -
| align="center" style="background:#F5F5F5;" |−
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal or mildly prolonged
| align="center" style="background:#F5F5F5;" |Nl or mildly prolonged
|Normal
| align="center" style="background:#F5F5F5;" |Nl
| -
| align="center" style="background:#F5F5F5;" |−
|}
|}


{| class="wikitable"
==Different types of Von-Willebrand diseases==
|+
{|
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:<ref name="pmid258585643">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of VWD
!Type of VWD
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of factor deficiency
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Prevalence
!Type of factor deficiency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inheritance pattern
!Prevalence
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
!Inheritance pattern
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |VWF activity
!Clinical manifestations
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RIPA
!VWF activity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Factor VIII
!RIPA
!Factor VIII
|-
|-
|Type 1
! colspan="2" align="center" style="background:#DCDCDC;" |Type 1
|
| align="center" style="background:#F5F5F5;" | Quantitative/ partial
|Quantitative/ partial
| align="center" style="background:#F5F5F5;" | 60-70%
|60-70%
| align="center" style="background:#F5F5F5;" | AD
|AD
| align="left" style="background:#F5F5F5;" |  
|
* Bleeding severity mild to severe
* Bleeding severity mild to severe
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↓
| align="center" style="background:#F5F5F5;" | ↓
|-
|-
| rowspan="4" |Type 2
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2
|2A<ref name="pmid1537829">{{cite journal |vauthors=Lyons SE, Bruck ME, Bowie EJ, Ginsburg D |title=Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations |journal=J. Biol. Chem. |volume=267 |issue=7 |pages=4424–30 |date=March 1992 |pmid=1537829 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |2A
|Qualitative
| align="center" style="background:#F5F5F5;" | Qualitative
|10%
| align="center" style="background:#F5F5F5;" | 10%
|AD/AR
| align="center" style="background:#F5F5F5;" | AD/AR
|
| align="left" style="background:#F5F5F5;" |  
* Moderate to severe bleeding
* Moderate to severe [[bleeding]]
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↓
| align="center" style="background:#F5F5F5;" | ↓
|N or ↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
|-
|2B
! align="center" style="background:#DCDCDC;" |2B
|Qualitative
| align="center" style="background:#F5F5F5;" | Qualitative
|5%
| align="center" style="background:#F5F5F5;" | 5%
|AD
| align="center" style="background:#F5F5F5;" | AD
|
| align="left" style="background:#F5F5F5;" |  
* [[Thrombocytopenia]]
* [[Thrombocytopenia]]
* Moderate to severe bleeding
* Moderate to severe [[bleeding]]
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↑
| align="center" style="background:#F5F5F5;" | ↑
|N or↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
|-
|2M
! align="center" style="background:#DCDCDC;" |2M
|Qualitative
| align="center" style="background:#F5F5F5;" | Qualitative
|<1%
| align="center" style="background:#F5F5F5;" | <1%
|AD/AR
| align="center" style="background:#F5F5F5;" | AD/AR
|
| align="left" style="background:#F5F5F5;" |  
* Moderate to severe bleeding
* Moderate to severe [[bleeding]]
|↓
| align="center" style="background:#F5F5F5;" | ↓
|↓
| align="center" style="background:#F5F5F5;" | ↓
|N or ↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
|-
|2N
! align="center" style="background:#DCDCDC;" |2N
|Qualitative
| align="center" style="background:#F5F5F5;" | Qualitative
|<1%
| align="center" style="background:#F5F5F5;" | <1%
|AR
| align="center" style="background:#F5F5F5;" | AR
|
| align="left" style="background:#F5F5F5;" |  
* Clinically similar to [[hemophilia A]] with joint, soft tissue, urinary bleeding
* Clinically similar to [[hemophilia A]] with [[joint]], [[soft tissue]], [[urinary]] [[bleeding]]
|N
| align="center" style="background:#F5F5F5;" | N
|N
| align="center" style="background:#F5F5F5;" | N
|↓
| align="center" style="background:#F5F5F5;" | ↓
|-
|-
|Type 3
! colspan="2" align="center" style="background:#DCDCDC;" |Type 3
|
| align="center" style="background:#F5F5F5;" | Complete deficiency
|Complete deficiency
| align="center" style="background:#F5F5F5;" | 1-2%
|1-2%
| align="center" style="background:#F5F5F5;" | AR
|AR
| align="left" style="background:#F5F5F5;" |  
|
* Clinically similar to [[hemophilia A]] with [[joint]] and [[soft tissue]] [[bleeding]]
* Clinically similar to [[hemophilia A]] with joint and soft tissue bleeding
* Severe [[mucosal bleeding]]
* Severe [[mucosal bleeding]]
|Absent
| align="center" style="background:#F5F5F5;" | Absent
|↓
| align="center" style="background:#F5F5F5;" | ↓
|
| align="center" style="background:#F5F5F5;" | Low, 1-10%
Low, 1-10%
|}
|}
For more information on Von Willebrand disease [[ von willebrand disease | click here]]
For more information on Von Willebrand disease, click [[ von willebrand disease | here]].


==References==
==References==
{{reflist|2}}
{{Reflist|2}}
<references />
 
{{WH}}
{{WS}}


[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Emergency medicine]]

Latest revision as of 20:38, 29 July 2020


Bleeding diathesis main page

Overview

Classification

Differential Diagnosis

Platelet disorders
Immune Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Hemolytic Uremic Syndrome
Thrombocytosis
Von Willebrand Disease
Coagulation disorders
Fibrinogen deficiency
Prothrombin deficiency
Factor V deficiency
Factor VII deficiency
Factor VIII deficiency
Factor IX deficiency
Factor X deficiency
Factor XI deficiency
Factor XII deficiency
High-molecular-weight kininogen deficiency
Prekallikrein deficiency
Factor XIII deficiency
Hemophilia
Rare diseases
Disseminated Intravascular Coagulation
Vitamin K Deficiency

Different types of Von-Willebrand diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Nazia Fuad M.D., Sogand Goudarzi, MD [3]

Synonyms and keywords: Hypocoagulopathy; blood coagulation disorders; hemorrhagic diathesis; hemostasis abnormality; bleeding tendency


Overview

Bleeding diathesis is susceptibility to bleed due to coagulopathy disorders or platelets disorders. These diseases can occur due to a disorder of homeostasis, localized process (tissue injury), or medications. Bleeding diathesis can be resulted from vessel wall injury, platelet disorders, and coagulation factor disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. Platelet disorders mostly have skin manifestations such as petechiae, and ecchymoses. In order to find the cause of hypo-coagulopathy; there are established laboratory tests, such as peripheral blood smear, platelet count and platelet function analysis, coagulation factor deficiencies and inhibitors, fibrinolysis tests (eg. D-dimer level), bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are CBC, PT, PTT, BT, and TT.

Classification

Disorders of hemostasis can be classified into two main categories: platelet disorders, and disorders of coagulation. Each category can be further classified as bellow:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abnormal hemostasis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

• Patient history-sign & symptom: deep soft tissue & mucocutaneus bleeding
• Screen test CBC-Plt-PT&PTT-BT-TT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hx of deep soft tissue bleeding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hx of mucocotaneus bleeding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulopathy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plt disorder
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family history
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal plt count
 
 
Low plt count
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(+)
• Inherited coagulpathy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(-)
• Acquired coagulopathy
 
 
 
 
 
 
Functional Plt disorder
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑Plt
• Hemophillia
• VWD
• Factor VIII or IX deficiency
 
↑PT
• Factor VII deficiency
 
↑PT&↑PTT
• Fibrinogen deficiency
• Factor II deficiency
• Factor V deficiency
• Factor X deficiency
 
 
↑PTT
• Factor inhibitor
• Anti phospholipid Ab syndrome
 
↑PT
• Factor inhibitor
• Vit K deficiency
• Liver disease
 
↑PT&↑PTT
• Factor inhibit
• DIC
• Liver failure
• Late stage of Vit K deficiency
 
↑ Afibrinogenemia
• Heparin inhibitor
• Direct thrombin inhibitor
 
 
 
 
Abnormal solobity
• Factor XIII deficiency
• Cross-linkin inhibitor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not corrected with mixing with NL plasma
 
 
 
 
 
 
 
 
HX(+)
 
HX(-)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

• Factor inhibitors
• Lupus anti coagulant
• DIC
• Heparin or direct thrombin inhibitors
 
 
 
 
 
 
 
 
Congenital
 
Acquired
 
 
 
 
 

Differentiating Bleeding Disorders from Other Diseases

Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.

These features have discussed in the below table:

Category Subcategory Disease History Clinical manifestation Laboratory testing Comments
Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia[1]
  • History of prior infection
+ + + + + + Nl Nl Nl
Medication-Induced Thrombocytopenia[2] + + + + + + Nl Nl Nl Most important part of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia[3] + + + + + + Nl Nl For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura[4] + + + + + + Nl Nl Nl
Inherited Thrombocytopenia[5]
  • Positive family history
+ + + + + + Nl Nl Nl
Thrombotic Thrombocytopenic Purpura[6] History of: + + + + + + Nl Nl Nl
Hemolytic Uremic Syndrome[7] History of: + + + + + + Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Thromobcytosis Iron deficiency anemia

Inflammatory diseases

Splenectomy

Essential thrombocytosis

± ± Nl or ↑ Nl Nl Nl
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + + Rare Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Wiskott-Aldrich syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • Anti-WASP antibody can be used to detect presence or absence of WAS protein
  • In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
Platelet storage pool disorder: + + + + Nl or ↓ Nl Nl Nl
  • AD inheritance
  • Abnormlities of platelet granule formation
Acquired Disorders of Platelet Function + + + + ± ± Nl or ↓ Nl Nl Nl
Von Willebrand Disease + + + + ± ± Nl Nl See the table below for the details about different types.
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease
+ + ± Nl Nl or ↑ Nl Nl Nl
Inherited Disorders of the Vessel Wall
  • Positive family history
+ + ± Nl Nl or ↑ Nl Nl Nl
Coagulation factor disorders

[8]

Fibrinogen deficiency

Different types of the fibrinogen disorders:

+ + ± + Nl
  • Impaired fibrin cross-linking or clot dissolution
  • Mild or severe bleeding depend on levels of functional fibrinogen
  • Variable age of onset
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Prothrombin deficiency + + + + + Nl Nl
Factor V deficiency + + + + Nl Nl
  • The severity of bleeding related to the degree of factor V deficiency
Factor VII deficiency + + + Nl Nl Nl
  • Thrombosis in inherited factor VII deficiency
  • Treatment with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
  • Easy bruising
  • Hematuria
  • Menorrhagia
  • Abortion
  • Postpartum hemorrhage
  • Epistaxis
  • Pseudotumors
  • Intracranial bleeding
  • Hemarthroses
+ + + + + Nl Nl Nl
Factor XII deficiency
  • Asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
Nl Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
High molecular weight kininogen (HMWK) deficiency
  • Positive family history of bleeding
Nl Nl Nl Nl
Prekallikrein deficiency
  • Positive family history of bleeding
Nl Nl Nl Nl
Factor XIII deficiency[9]
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Positive family history of bleeding
± ± ± ± ± ± Nl Nl Nl or ↑ Nl Nl
  • Impaired fibrin cross-linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia[10] Type A deficiency + + + Nl Nl Nl Nl
Type B deficiency + + + Nl Nl Nl Nl
Type C deficiency
  • Positive family history
  • Bleeding after surgery or injury
+ Rare Rare Nl Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Rare diseases Disseminated Intravascular Coagulation[11][12][13][14][15] + + + + + + Nl
Vitamin K Deficiency[16] + + + + + Nl Nl or mildly prolonged Nl

Different types of Von-Willebrand diseases

Type of VWD Type of factor deficiency Prevalence Inheritance pattern Clinical manifestations VWF activity RIPA Factor VIII
Type 1 Quantitative/ partial 60-70% AD
  • Bleeding severity mild to severe
Type 2 2A Qualitative 10% AD/AR N or ↓
2B Qualitative 5% AD N or ↓
2M Qualitative <1% AD/AR N or ↓
2N Qualitative <1% AR N N
Type 3 Complete deficiency 1-2% AR Absent Low, 1-10%

For more information on Von Willebrand disease, click here.

References

  1. Herbinger, K.-H.; Schunk, M.; Nothdurft, H. D.; von Sonnenburg, F.; Löscher, T.; Bretzel, G. (2012). "Comparative study on infection-induced thrombocytopenia among returned travellers". Infection. 40 (4): 373–379. doi:10.1007/s15010-012-0242-9. ISSN 0300-8126.
  2. Elting, Linda S.; Cantor, Scott B.; Martin, Charles G.; Hamblin, Lois; Kurtin, Danna; Rivera, Edgardo; Vadhan-Raj, Saroj; Benjamin, Robert S. (2003). "Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors". Cancer. 97 (6): 1541–1550. doi:10.1002/cncr.11195. ISSN 0008-543X.
  3. Miller, Penny L. (2003). "Heparin-induced Thrombocytopenia Recognition and Treatment". AORN Journal. 78 (1): 79–89. doi:10.1016/S0001-2092(06)61348-3. ISSN 0001-2092.
  4. Curtis, Brian R.; Kaliszewski, James; Marques, Marisa B.; Saif, M. Wasif; Nabelle, Lisle; Blank, Jules; McFarland, Janice G.; Aster, Richard H. (2006). "Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin". American Journal of Hematology. 81 (3): 199–201. doi:10.1002/ajh.20516. ISSN 0361-8609.
  5. Drachman, J. G. (2004). "Inherited thrombocytopenia: when a low platelet count does not mean ITP". Blood. 103 (2): 390–398. doi:10.1182/blood-2003-05-1742. ISSN 0006-4971.
  6. George, James N. (2006). "Thrombotic Thrombocytopenic Purpura". New England Journal of Medicine. 354 (18): 1927–1935. doi:10.1056/NEJMcp053024. ISSN 0028-4793.
  7. Noris, M. (2005). "Hemolytic Uremic Syndrome". Journal of the American Society of Nephrology. 16 (4): 1035–1050. doi:10.1681/ASN.2004100861. ISSN 1046-6673.
  8. Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. (2015). "Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis;". 41 (3 (41)): 323–329.
  9. Peyvandi F, Garagiola I, Young G (July 2016). "The past and future of haemophilia: diagnosis, treatments, and its complications". Lancet. 388 (10040): 187–97. doi:10.1016/S0140-6736(15)01123-X. PMID 26897598.
  10. Siegal T, Seligsohn U, Aghai E, Modan M (February 1978). "Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases". Thromb. Haemost. 39 (1): 122–34. PMID 580488.
  11. Levi M, Toh CH, Thachil J, Watson HG (April 2009). "Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology". Br. J. Haematol. 145 (1): 24–33. doi:10.1111/j.1365-2141.2009.07600.x. PMID 19222477.
  12. Ghosh K, Shetty S (March 2008). "Blood coagulation in falciparum malaria--a review". Parasitol. Res. 102 (4): 571–6. doi:10.1007/s00436-007-0832-0. PMID 18066597.
  13. Siegal T, Seligsohn U, Aghai E, Modan M (February 1978). "Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases". Thromb. Haemost. 39 (1): 122–34. PMID 580488.
  14. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (March 1992). "Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies". Chest. 101 (3): 816–23. PMID 1531791.
  15. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG (2006). "Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis". Arch Intern Med. 166 (4): 391–7. doi:10.1001/.391. PMID 16505257.